Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes
Diabetes Care2009Vol. 32(10), pp. 1880–1886
Citations Over TimeTop 1% of 2009 papers
Julio Rosenstock, Jane E.B. Reusch, Mark Bush, Fred Yang, Murray Stewart, for the Albiglutide Study Group
Abstract
Weekly albiglutide administration significantly improved glycemic control and elicited weight loss in type 2 diabetic patients, with a favorable safety and tolerability profile.
Related Papers
- → Liraglutide vs Exenatide: Patient Adherence, Medication Persistence and Economic Evaluation in the Treatment of Type 2 Diabetes Mellitus(2014)3 cited
- → Use of exenatide and liraglutide in Denmark: a drug utilization study(2013)12 cited
- → Is liraglutide or exenatide better in type 2 diabetes?(2009)2 cited
- → Behandlung des Diabetes mellitus Typ 2: Exenatid oder Liraglutid? - Exenatid und Liraglutid im „head-to head“-Vergleich in etwa gleichrangig(2013)
- Liraglutide. Type 2 diabetes: more prudent to continue using exenatide.(2010)